
Biolevate is a VC-backed, early-stage B2B startup that leverages GenAI & ML to accelerate therapeutic innovation. Their all-in-one workflow automation SaaS platform helps life science professionals analyze, prioritize, and act on complex biological data faster. The company was founded in 2023 with a belief in a future where healthcare innovations meet ethical AI, enabling simple, secure, and collaborative solutions. Biolevate's powerful features include automated data extraction, predictive analytics, and centralized project management tools designed for compliance, security, and operational efficiency. They focus on solutions for Curation & Screening, Content Generation, and Research & Literature Monitoring, aiming to reduce development costs and time-to-market for new therapies.

Biolevate is a VC-backed, early-stage B2B startup that leverages GenAI & ML to accelerate therapeutic innovation. Their all-in-one workflow automation SaaS platform helps life science professionals analyze, prioritize, and act on complex biological data faster. The company was founded in 2023 with a belief in a future where healthcare innovations meet ethical AI, enabling simple, secure, and collaborative solutions. Biolevate's powerful features include automated data extraction, predictive analytics, and centralized project management tools designed for compliance, security, and operational efficiency. They focus on solutions for Curation & Screening, Content Generation, and Research & Literature Monitoring, aiming to reduce development costs and time-to-market for new therapies.
Stage: Seed (Nov 2024)
Focus: GenAI/ML SaaS for life-sciences documentation and workflow automation
Headquarters: Paris
Recent raise: 6 6 million (~€6M) led by EQT Ventures
Curation & screening, scientific and regulatory document creation, and research/literature monitoring for life sciences.
2023
Biotechnology
,000,000
Seed round led by EQT Ventures with participation from Bpifrance and angel investor Mehdi Ghissassi
“Raised a M seed led by EQT Ventures; participation from public/mission-oriented investor Bpifrance and angel investors”